Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group

K P E Glahn; F R Ellis; P J Halsall; C R Müller; M M J Snoeck; A Urwyler; F Wappler; European Malignant Hyperthermia Group

doi:10.1093/bja/aeq243

Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group

K P E Glahn, F R Ellis, P J Halsall, C R Müller, M M J Snoeck, A Urwyler, F Wappler, European Malignant Hyperthermia Group

Anaesthesiology Herlev

141 Citations (Scopus)

Abstract

Survival from a malignant hyperthermia (MH) crisis is highly dependent on early recognition and prompt action. MH crises are very rare and an increasing use of total i.v. anaesthesia is likely to make it even rarer, leading to the potential risk of reduced awareness of MH. In addition, dantrolene, the cornerstone of successful MH treatment, is unavailable in large areas around the world thereby increasing the risk of MH fatalities in these areas. The European Malignant Hyperthermia Group collected and reviewed all guidelines available from the various MH centres in order to provide a consensus document. The guidelines consist of two textboxes: Box 1 on recognizing MH and Box 2 on the treatment of an MH crisis.

Original language	English
Journal	British Journal of Anaesthesia
Volume	105
Issue number	4
Pages (from-to)	417-20
Number of pages	4
ISSN	0007-0912
DOIs	https://doi.org/10.1093/bja/aeq243
Publication status	Published - 1 Oct 2010

Keywords

Diagnosis, Differential
Early Diagnosis
Humans
Malignant Hyperthermia

Access to Document

10.1093/bja/aeq243

Cite this

@article{1e4161769912447d847fb705431413de,

title = "Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group",

abstract = "Survival from a malignant hyperthermia (MH) crisis is highly dependent on early recognition and prompt action. MH crises are very rare and an increasing use of total i.v. anaesthesia is likely to make it even rarer, leading to the potential risk of reduced awareness of MH. In addition, dantrolene, the cornerstone of successful MH treatment, is unavailable in large areas around the world thereby increasing the risk of MH fatalities in these areas. The European Malignant Hyperthermia Group collected and reviewed all guidelines available from the various MH centres in order to provide a consensus document. The guidelines consist of two textboxes: Box 1 on recognizing MH and Box 2 on the treatment of an MH crisis.",

keywords = "Diagnosis, Differential, Early Diagnosis, Humans, Malignant Hyperthermia",

author = "Glahn, {K P E} and Ellis, {F R} and Halsall, {P J} and M{\"u}ller, {C R} and Snoeck, {M M J} and A Urwyler and F Wappler and {European Malignant Hyperthermia Group}",

year = "2010",

month = oct,

day = "1",

doi = "10.1093/bja/aeq243",

language = "English",

volume = "105",

pages = "417--20",

journal = "British Journal of Anaesthesia",

issn = "0007-0912",

publisher = "Oxford University Press",

number = "4",

}

TY - JOUR

T1 - Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group

AU - Glahn, K P E

AU - Ellis, F R

AU - Halsall, P J

AU - Müller, C R

AU - Snoeck, M M J

AU - Urwyler, A

AU - Wappler, F

AU - European Malignant Hyperthermia Group

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Survival from a malignant hyperthermia (MH) crisis is highly dependent on early recognition and prompt action. MH crises are very rare and an increasing use of total i.v. anaesthesia is likely to make it even rarer, leading to the potential risk of reduced awareness of MH. In addition, dantrolene, the cornerstone of successful MH treatment, is unavailable in large areas around the world thereby increasing the risk of MH fatalities in these areas. The European Malignant Hyperthermia Group collected and reviewed all guidelines available from the various MH centres in order to provide a consensus document. The guidelines consist of two textboxes: Box 1 on recognizing MH and Box 2 on the treatment of an MH crisis.

AB - Survival from a malignant hyperthermia (MH) crisis is highly dependent on early recognition and prompt action. MH crises are very rare and an increasing use of total i.v. anaesthesia is likely to make it even rarer, leading to the potential risk of reduced awareness of MH. In addition, dantrolene, the cornerstone of successful MH treatment, is unavailable in large areas around the world thereby increasing the risk of MH fatalities in these areas. The European Malignant Hyperthermia Group collected and reviewed all guidelines available from the various MH centres in order to provide a consensus document. The guidelines consist of two textboxes: Box 1 on recognizing MH and Box 2 on the treatment of an MH crisis.

KW - Diagnosis, Differential

KW - Early Diagnosis

KW - Humans

KW - Malignant Hyperthermia

U2 - 10.1093/bja/aeq243

DO - 10.1093/bja/aeq243

M3 - Journal article

C2 - 20837722

VL - 105

SP - 417

EP - 420

JO - British Journal of Anaesthesia

JF - British Journal of Anaesthesia

SN - 0007-0912

IS - 4

ER -

Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group

Abstract

Keywords

Access to Document

Fingerprint

Cite this